S
SAB Biotherapeutics, Inc.
SABS · NASDAQ · Healthcare · 337M
Closing price
$2.98
+3.11% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
4.3×
Price / net assetsP/B
0.4×
Enterprise value / EBITDAEV/EBITDA
3.2×
Free cash flow yieldFCF yield
-79.4%
Return on equityROE
8.8%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
-0.3×
Interest coverage
-203.4×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.